Veille Coronavirus - Covid-19
60.3K views | +1 today
Follow
Veille Coronavirus - Covid-19
Your new post is loading...
Scooped by HAS-veille
August 7, 2023 6:32 AM
Scoop.it!

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness - Lancet Respir Med

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness - Lancet Respir Med | Veille Coronavirus - Covid-19 | Scoop.it
Despite advances in the treatment and mitigation of critical illness caused by infection with SARS-CoV-2, millions of survivors have a devastating, po…
No comment yet.
Scooped by HAS-veille
August 7, 2023 4:01 AM
Scoop.it!

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
July 13, 2023 8:43 AM
Scoop.it!

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - Lancet I...

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - Lancet I... | Veille Coronavirus - Covid-19 | Scoop.it
Bivalent BA.1 booster vaccines were offered to adults aged 50 years or older and clinically vulnerable people as part of the 2022 autumn COVID-19 boos…
No comment yet.
Scooped by HAS-veille
July 12, 2023 7:58 AM
Scoop.it!

SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non-systematic literature review for surveillance purposes

SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non-systematic literature review for surveillance purposes | Veille Coronavirus - Covid-19 | Scoop.it
Antiviral drugs and monoclonal antibodies (mAbs), administered either separately or as combination therapy 'cocktails’, have provided a valuable tool for fighting COVID-19. Surveillance data, coupled with data on antiviral treatment susceptibility, can guide clinical decisions on selecting the best therapy for the patient.
No comment yet.
Scooped by HAS-veille
July 12, 2023 4:26 AM
Scoop.it!

Gene linked to long COVID found in analysis of thousands of patients

Gene linked to long COVID found in analysis of thousands of patients | Veille Coronavirus - Covid-19 | Scoop.it
The first genome-wide search for long-COVID risk factors could pave the way for larger studies.
No comment yet.
Scooped by HAS-veille
July 4, 2023 8:21 AM
Scoop.it!

Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection: A Prospective Cohort Study: Annals of Internal Medicine: Vol 0, No 0

Background: The performance of rapid antigen tests (Ag-RDTs) for screening asymptomatic and symptomatic persons for SARS-CoV-2 is not well established. Objective: To evaluate the performance of Ag-RDTs for detection of SARS-CoV-2 among symptomatic and asymptomatic participants. Design: This prospective cohort study enrolled participants between October 2021 and January 2022. Participants completed Ag-RDTs and reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 every 48 hours for 15 days. Setting: Participants were enrolled digitally throughout the mainland United States. They self-collected anterior nasal swabs for Ag-RDTs and RT-PCR testing. Nasal swabs for RT-PCR were shipped to a central laboratory, whereas Ag-RDTs were done at home. Participants: Of 7361 participants in the study, 5353 who were asymptomatic and negative for SARS-CoV-2 on study day 1 were eligible. In total, 154 participants had at least 1 positive RT-PCR result. Measurements: The sensitivity of Ag-RDTs was measured on the basis of testing once (same-day), twice (after 48 hours), and thrice (after a total of 96 hours). The analysis was repeated for different days past index PCR positivity (DPIPPs) to approximate real-world scenarios where testing initiation may not always coincide with DPIPP 0. Results were stratified by symptom status. Results: Among 154 participants who tested positive for SARS-CoV-2, 97 were asymptomatic and 57 had symptoms at infection onset. Serial testing with Ag-RDTs twice 48 hours apart resulted in an aggregated sensitivity of 93.4% (95% CI, 90.4% to 95.9%) among symptomatic participants on DPIPPs 0 to 6. When singleton positive results were excluded, the aggregated sensitivity on DPIPPs 0 to 6 for 2-time serial testing among asymptomatic participants was lower at 62.7% (CI, 57.0% to 70.5%), but it improved to 79.0% (CI, 70.1% to 87.4%) with testing 3 times at 48-hour intervals. Limitation: Participants tested every 48 hours; therefore, these data cannot support conclusions about serial testing intervals shorter than 48 hours. Conclusion: The performance of Ag-RDTs was optimized when asymptomatic participants tested 3 times at 48-hour intervals and when symptomatic participants tested 2 times separated by 48 hours. Primary Funding Source: National Institutes of Health RADx Tech program.
No comment yet.
Scooped by HAS-veille
June 28, 2023 3:57 AM
Scoop.it!

Long COVID: answers emerge on how many people get better

Long COVID: answers emerge on how many people get better | Veille Coronavirus - Covid-19 | Scoop.it
Studies are shedding light on rates of recovery as well as the prevention and treatment of the complex condition.
No comment yet.
Scooped by HAS-veille
June 21, 2023 10:35 AM
Scoop.it!

Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study - Lancet Infect Dis

Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study - Lancet Infect Dis | Veille Coronavirus - Covid-19 | Scoop.it
COVID-19 continues to be a major health threat, particularly among at-risk groups, including individuals aged 60 years or older and people with partic…
No comment yet.
Scooped by HAS-veille
June 21, 2023 10:34 AM
Scoop.it!

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients - Lancet Infect Dis

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients - Lancet Infect Dis | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
June 21, 2023 3:51 AM
Scoop.it!

Comparison of Medical and Mental Health Sequelae Following Hospitalization for COVID-19, Influenza, and Sepsis | Critical Care Medicine | JAMA Internal Medicine

Comparison of Medical and Mental Health Sequelae Following Hospitalization for COVID-19, Influenza, and Sepsis | Critical Care Medicine | JAMA Internal Medicine | Veille Coronavirus - Covid-19 | Scoop.it
This cohort study measures the associated long-term effects of COVID-19 that are distinct from the risks associated with hospitalization for acute illnesses in general.
No comment yet.
Scooped by HAS-veille
June 14, 2023 3:49 AM
Scoop.it!

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study - Lancet

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study - Lancet | Veille Coronavirus - Covid-19 | Scoop.it
The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patie…
No comment yet.
Scooped by HAS-veille
June 8, 2023 10:18 AM
Scoop.it!

Severe SARS-CoV-2 infection as a marker of undiagnosed cancer: a population-based study | Scientific Reports

Severe SARS-CoV-2 infection as a marker of undiagnosed cancer: a population-based study | Scientific Reports | Veille Coronavirus - Covid-19 | Scoop.it
No study has yet investigated if a severe SARS-CoV-2 infection represents a marker of an undiagnosed cancer. This population-based study, using the SNDS database, identified from 02/15/2020 to 08/31/2021, 41,302 individuals hospitalized in intensive care unit due to SARS-CoV-2 (ICU-gr) and 713,670 control individuals not hospitalized for SARS-CoV-2 (C-gr). Individuals were matched according to year of birth, sex and French department. The cancer incidence was compared in the two groups during the follow-up period (index date-12/31/2021), using Cox proportional hazards models adjusted on matching variables, socioeconomic characteristics and comorbidities. In the ICU-gr, 2.2% (n = 897) was diagnosed with a cancer in the following months, compared to 1.5% (n = 10,944) in the C-gr. The ICU-gr had a 1.31 higher risk of being diagnosed with a cancer following hospital discharge compared to the C-gr (aHR 1.31, 95% CI 1.22–1.41). A global similar trend was found when competing risk of death was taken into account (aHR 1.25, 95% CI 1.16–1.34). A significant higher risk was found concerning renal (aHR 3.16, 95% CI 2.33–4.27), hematological (aHR 2.54, 95% CI 2.07–3.12), colon (aHR 1.72, 95% CI 1.34–2.21), and lung (aHR 1.70, 95% CI 1.39–2.08) cancers. This suggests that a severe SARS-CoV-2 infection may represent a marker of an undiagnosed cancer.
HAS-veille's insight:

étude française

No comment yet.
Scooped by HAS-veille
June 5, 2023 1:32 AM
Scoop.it!

Recent Insights on Post-COVID in Pediatrics : Ped Infect Dis J

Recent Insights on Post-COVID in Pediatrics : Ped Infect Dis J | Veille Coronavirus - Covid-19 | Scoop.it
An abstract is unavailable.
No comment yet.
Scooped by HAS-veille
August 7, 2023 6:31 AM
Scoop.it!

Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations - Lancet Respir Med

Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations - Lancet Respir Med | Veille Coronavirus - Covid-19 | Scoop.it
Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the acute phase of COVID-19 or emerge after the acute phase, lasti…
No comment yet.
Scooped by HAS-veille
August 7, 2023 12:58 AM
Scoop.it!

From Asymptomatic Covid to Long Covid: Major Advances in Genetic Underpinnings

From Asymptomatic Covid to Long Covid: Major Advances in Genetic Underpinnings | Veille Coronavirus - Covid-19 | Scoop.it
Today in Nature a groundbreaking and compelling report on the genomics of why some people do not manifest symptoms of Covid. And last week 2 papers (here and here) on the genetics of Long Covid. This represents genetic probes for the extreme of the clinical spectrum—from not exhibiting symptoms of SARS-CoV-2 infection to developing a debilitating, chronic condition. In this edition of Ground Truths, I’ll review the 3 new studies and contextualize their importance.
No comment yet.
Scooped by HAS-veille
July 13, 2023 8:43 AM
Scoop.it!

Effectiveness of monovalent and bivalent COVID-19 vaccines - Lancet Infect Dis

Effectiveness of monovalent and bivalent COVID-19 vaccines - Lancet Infect Dis | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
July 12, 2023 6:35 AM
Scoop.it!

The immunology of long COVID | Nature Reviews Immunology

The immunology of long COVID | Nature Reviews Immunology | Veille Coronavirus - Covid-19 | Scoop.it
Long COVID is the patient-coined term for the disease entity whereby persistent symptoms ensue in a significant proportion of those who have had COVID-19, whether asymptomatic, mild or severe. Estimated numbers vary but the assumption is that, of all those who had COVID-19 globally, at least 10% have long COVID. The disease burden spans from mild symptoms to profound disability, the scale making this a huge, new health-care challenge. Long COVID will likely be stratified into several more or less discrete entities with potentially distinct pathogenic pathways. The evolving symptom list is extensive, multi-organ, multisystem and relapsing–remitting, including fatigue, breathlessness, neurocognitive effects and dysautonomia. A range of radiological abnormalities in the olfactory bulb, brain, heart, lung and other sites have been observed in individuals with long COVID. Some body sites indicate the presence of microclots; these and other blood markers of hypercoagulation implicate a likely role of endothelial activation and clotting abnormalities. Diverse auto-antibody (AAB) specificities have been found, as yet without a clear consensus or correlation with symptom clusters. There is support for a role of persistent SARS-CoV-2 reservoirs and/or an effect of Epstein–Barr virus reactivation, and evidence from immune subset changes for broad immune perturbation. Thus, the current picture is one of convergence towards a map of an immunopathogenic aetiology of long COVID, though as yet with insufficient data for a mechanistic synthesis or to fully inform therapeutic pathways. SARS-CoV-2 infection can lead to a diverse array of chronic symptoms, collectively termed ‘long COVID’. In this Review, Altmann and colleagues explore current thinking about the pathophysiology of long COVID and discuss potential immunological mechanisms.
No comment yet.
Scooped by HAS-veille
July 6, 2023 6:25 AM
Scoop.it!

Global regulators confirm good safety profile of COVID-19 vaccines

Global regulators confirm good safety profile of COVID-19 vaccines | Veille Coronavirus - Covid-19 | Scoop.it
Global regulators confirm good safety profile of COVID-19 vaccines
No comment yet.
Scooped by HAS-veille
July 3, 2023 2:36 AM
Scoop.it!

Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis | Adolescent Medicine | JAMA Network Open

Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis | Adolescent Medicine | JAMA Network Open | Veille Coronavirus - Covid-19 | Scoop.it
This systematic review and meta-analysis compares incidence rates of diabetes and diabetic ketoacidosis among children and adolescents before and during the COVID-19 pandemic.
No comment yet.
Scooped by HAS-veille
June 27, 2023 3:08 AM
Scoop.it!

Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies

In this Personal View, we discuss current knowledge on SARS-CoV-2 RNA or antigen persistence
in children infected with SARS-CoV-2. Based on the evidence that the virus can persist
in adults, we have done a literature review and analysed studies that looked for SARS-CoV-2
RNA or antigens in children undergoing autopsy, biopsy, or surgery for either death
from COVID-19 or multisystem inflammatory syndrome, or assessments for long COVID-19
or other conditions. Our analysis suggests that in children, independent from disease
severity, SARS-CoV-2 can spread systemically and persist for weeks to months.
No comment yet.
Scooped by HAS-veille
June 21, 2023 10:34 AM
Scoop.it!

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial - Lancet Inf...

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial - Lancet Inf... | Veille Coronavirus - Covid-19 | Scoop.it
Aerosolised Ad5-nCoV is one of the first licensed mucosal respiratory vaccine against SARS-CoV-2 in the world; however, the safety profile of this vac…
No comment yet.
Scooped by HAS-veille
June 21, 2023 4:06 AM
Scoop.it!

Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project) | BMJ Open

Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project) | BMJ Open | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
June 14, 2023 8:46 AM
Scoop.it!

The Effectiveness of COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Analyses of Data from the UK, Spain, and Estonia

The Effectiveness of COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Analyses of Data from the UK, Spain, and Estonia | Veille Coronavirus - Covid-19 | Scoop.it
Background: While vaccines have proved effective to prevent severe COVID-19, their impact to prevent long-term symptoms is not yet fully understood.
No comment yet.
Scooped by HAS-veille
June 9, 2023 12:37 PM
Scoop.it!

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial - Lancet Infect Dis

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial - Lancet Infect Dis | Veille Coronavirus - Covid-19 | Scoop.it
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate wheth…
No comment yet.
Scooped by HAS-veille
June 6, 2023 9:37 AM
Scoop.it!

EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants

EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants | Veille Coronavirus - Covid-19 | Scoop.it
EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants
No comment yet.